RemeGen Ltd (HKG: 9995) has announced that it has received approval from the Human Research Ethics Committees of Australia to conduct a Phase I clinical study for its investigational drug RC198. The study will focus on patients with locally advanced unresectable or metastatic solid tumors.
RC198: An Fc Fusion Protein Targeting IL-15 and IL-15R α
RC198 is an Fc fusion protein that targets interleukin-15 (IL-15) and interleukin-15 receptor α (IL-15R α). It is under development for the treatment of a variety of solid tumor types, including urothelial cancer, melanoma, cervical cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, and more. The drug’s potential to address a broad spectrum of cancers highlights its significance in the field of oncology.
Clinical Trial Progression and Global Reach
The drug has recently been filed for clinical trials in China, indicating RemeGen’s commitment to expanding the global reach of its investigational therapies. The upcoming Phase I clinical study in Australia marks a crucial step in evaluating the safety, tolerability, and preliminary efficacy of RC198 in humans.-Fineline Info & Tech
